PARIS (Reuters) - Stallergènes received in 2012 accelerated its development in Australia and Canada to offset difficult conditions in Europe Sud.
SalesFrench laboratory specialized in the treatment of allergies have increased by 3.3% last year. In October, the group stated that its growth rate would be around 5% .
In a statement, Stallergènes stressed that its operating profit is expected to be "at the outcome of the year 2011", excluding the impact of the new measures fiscales.
The group will publish its 2012 results on 7 mars.
sales Stallergènes 2012, which develops products desensitization well known victims of hay fever or mites, reached 242.6 million euros, including 69.3 million in the fourth quarter (0.7% ) .
The annual sales in the "new countries" group (Australia, Canada, Russia, Middle East, Latin America) grew by 27.6% while that of Southern Europe (Portugal, Spain, France, Italy) registering an increase of only 4% .
New markets have contributed to 38% growth annuelle.
Oralair, treatment Stallergènes flagship, is now marketed in 19 countries and is now being launched in Hungary, Lithuania and Latvia. This tablet has seen its sales grow 33% in 2012 to 16.2 million .
In an interview with Reuters late December, Roberto Gradnik, CEO Stallergènes had hoped realize from 2013 acquisitions to accelerate its expansion internationale.
He stated aim particularly "attractive markets" in Argentina and Brazil, while stressing that Stallergènes also wanted to strengthen Germany and Etats-Unis.
action Stallergènes closed Monday at 41.53 euros (0.07%) at the Paris Stock Exchange, bringing its market capitalization to 559.4 million euros. It grew by 1.9% since the beginning of the year .
Noelle Mennella, edited by Matthias Blamont
No comments:
Post a Comment